1. A display apparatus comprising:
a plurality of light emitting device groups including light emitting devices emitting lights of different colors,
wherein each of the light emitting devices includes a first electrode, a second electrode, a light emitting layer located between the first and second electrodes, and an optical path between a first reflection plane located near the first electrode and a second reflection plane located near the second electrode is set so that light emitted through the light emitting layer is resonated,
wherein a member configured to absorb a predetermined wavelength range for light emitted in a direction having an angle with respect to a normal direction of the display apparatus is located on a light extracting side of the second electrode, and
wherein the predetermined wavelength range is set so that a hue of light emitted in the direction having the angle becomes yellow when the light-emitting-device group emits white light.
2. The display apparatus according to claim 1, wherein the member includes a light transmission part through which incident light is passed and a color absorbing part to absorb the predetermined wavelength range of the incident light.
3. The display apparatus according to claim 2 herein the light transmission part is on a light extracting side of the light emitting devices, and the color absorbing part is on a light extracting side.
4. The display apparatus according to claim 1,
wherein the member includes a first polarization member, a retardation member, and a second polarization member that are sequentially located on a light extracting side of the light emitting device group.
5. The display apparatus according to claim 4,
wherein a \u03bb4 retardation member is located between the first polarization member and the light emitting device group.
6. The display apparatus according to claim 1,
wherein the member is a member in which at least one dichromatic dye is oriented in the normal direction.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treatment of a host with a cellular proliferative disease, comprising contacting said host with a naphthalimide in conjunction with an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, wherein said cellular proliferative disease is a solid tumor.
2. The method according to claim 1, wherein said naphthalimide comprises amonafide and said antiproliferative agent is cisplastin.
3. The method according to claim 1, wherein said naphthalimide comprises amonafide and said antiproliferative agent is 5-FU.
4. The method according to claim 1, wherein said naphthalimide comprises amonafide and said antiproliferative agent is genistein.
5. The method according to claim 1, wherein said naphthalimide comprises amonafide and said antiproliferative agent is rosmarinic acid.
6. The method according to claim 1, wherein said naphthalimide comprises amonafide and said antiproliferative agent is camptothecin.
7. The method according to claim 1, wherein said naphthalimide comprises an amonafide analog.
8. The method according to claim 1, wherein said antiproliferative agent comprises an agent that interacts with nucleic acids.
9. The method according to claim 1, wherein said antiproliferative agent comprises an alkylating agent, an intercalating agent, a metal coordination complex, a pyrimidine nucleoside, a purine nucleoside, an inhibitor of nucleic acid associated enzymes, or an inhibitor of nucleic acid associated proteins.
10. The method according to claim 1, wherein said host is a human.
11. The method according to claim 1, wherein said naphthalimide is administered before the administration of said antiproliferative agent.
12. The method according to claim 1, wherein said naphthalimide is administered during the administration of said antiproliferative agent.
13. The method according to claim 1, wherein said naphthalimide is administered after the administration of said antiproliferative agent.
14. The method according to claim 11, wherein said naphthalimide is administered less than 4 hours before the administration of said antiproliferative agent.
15. The method according to claim 13, wherein said naphthalimide is administered less than 4 hours after the administration of said antiproliferative agent.
16. The method according to claim 1, wherein the modulation of said disease with said composition is greater than that for said antiproliferative agent alone.
17. A composition comprising a naphthalimide and an antiproliferative agent, wherein said antiproliferative agent is genistein.
18. A composition comprising a naphthalimide and an antiproliferative agent, wherein said antiproliferative agent is rosmarinic acid.
19. A composition comprising a naphthalimide and an antiproliferative agent, wherein said antiproliferative agent is camptothecin.